Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MKC253

Other · developed by Mannkind

Phase 1 Most advanced trial (none active)
MNKD Developer
1 Registered trials

What is MKC253?

MKC253 is an investigational drug studied in Diabetes Mellitus, Type 2, Healthy Males.

At a glance

Drug type
Other
Therapy area
Endocrine
Developer
Mannkind Corporation (MNKD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00475371 Phase 1 Diabetes Mellitus, Type 2 Completed MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 2Healthy Males

More from Mannkind

Follow MNKD, the company behind MKC253

See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNKD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.